Article

InSite obtains rights to optineurin gene

A test for the optineurin gene will be available to ophthalmologists soon - possibly this year and certainly by 2003, said S. Kumar Chandrasekaran, PhD, CEO of InSite Vision, Alameda, CA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Tiimes) EyeCon 2025: Sruthi Arepalli, MD, spotlights a deep dive orbital tour of the eye
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Related Content
New company OpZira formed following Alcon’s acquisition of LumiThera
September 16th 2025

New company OpZira formed following Alcon’s acquisition of LumiThera

3 Things You Should Know About the GA Pipeline
September 16th 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

(Image credit: AdobeStock/Harsha) Inside Northwestern University’s “Dinner with the Experts” educational series with Robert S. Feder, MD
September 16th 2025

Q&A: Inside Northwestern University’s “Dinner with the Experts” educational series with Robert S. Feder, MD

3 Things You Should Know About the GA Pipeline
September 16th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: SeeWhatMatters)
September 16th 2025

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

(Image credit: Ophthalmology Times) From firsts to the future: A pioneer's perspective on ophthalmology
September 16th 2025

From firsts to the future: A pioneer's perspective on ophthalmology

© 2025 MJH Life Sciences

All rights reserved.